ArticleEmerging microbes & infections2025
Incidence and determinants of achieving HBsAg <100 IU/mL in HBeAg-negative CHB patients with nucleos(t)ide analogue treatment.
Article in Emerging microbes & infections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Virologic Response to Antiviral Therapy in Chronic Hepatitis B Patients With High Viral Load: A Real-World Cohort Study.Journal of viral hepatitis · 2026Article
- Long-term Dynamic Virological Response Patterns and Clinical Outcomes in Hepatitis B Virus-related Cirrhosis: A Real-world 10-year Cohort Study.Journal of clinical and translational hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Quantitative hepatitis B serum antigen (HBsAg) level <100 IU/mL has been proposed as one of the key criteria for partial cure for chronic hepatitis B (CHB) and as an important threshold for stopping nucleos(t)ide analogues (NAs) with a finite therapeutic strategy. We investigated the incidence and associated factors of HBsAg<100 IU/mL in hepatitis B e antigen (HBeAg)-negative CHB patients initiating NAs therapy. A total of 996 HBeAg-negative CHB patients with baseline HBsAg>100 IU/mL initiating first-line NAs treatment from five hospitals in China were retrospectively included. Cumulative incidence and associated factors of HBsAg<100 IU/mL were assessed using Kaplan-Meier and Cox regression analyses, respectively. During a median follow-up of 28.8 months, 69 patients (6.9%) achieved HBsAg<100 IU/mL, with a 5-year cumulative incidence of 13.97% (95%CI: 10.42%-17.38%). Among them, 94.2% (65/69) achieved both HBsAg<100 IU/mL and undetectable HBV DNA, with a 5-year incidence of 13.15% (95%CI: 9.66%-16.50%). Baseline HBsAg<1000 IU/mL (aHR = 19.66, 95%CI: 8.84-43.71, P<0.001) and HBV DNA<10,000 IU/mL (aHR = 2.47, 95%CI: 1.48-4.13,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.